GlassScriptPhysician profile
Alan W Keister
NPI 1255373635
$5,503.79
in general payments reported to CMS, 2019-2025
30 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,429 · 2020: $229 · 2021: $27.28 · 2022: $105 · 2023: $678 · 2024: $1,732 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $794.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $650.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $628.22 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $436.69 | 2019-2025 | |
| Lilly USA, LLC | $380.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $355.03 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $302.49 | 2019-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $262.74 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $249.46 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $219.96 | 2019-2025 | Spravato |
| Phathom Pharmaceuticals, INC. | $216.63 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $172.09 | 2019-2025 | |
| Amarin Pharma, INC. | $167.46 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.27 | 2019-2025 | Jardiance |
| Inspire Medical Systems, INC. | $100.45 | 2024 | Inspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $67.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.52 | 2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $39.21 | 2019-2023 | Belsomra, Steglatro |
| Lundbeck LLC | $34.47 | 2023 | Rexulti, Vyepti |
| Sanofi-Aventis U.S. LLC | $29.64 | 2019 | |
| Allergan, INC. | $27.67 | 2019 | |
| Abbott Laboratories | $20.33 | 2024 | Freestyle Libre 3 |
| Medtronic, INC. | $18.33 | 2024 | Intellis Adaptivestim |
| Antares Pharma, INC. | $17.07 | 2020 | |
| Dexcom, INC. | $16.47 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.84 | 2019 | |
| Neurocrine Biosciences, INC. | $14.87 | 2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $14.02 | 2023 | Quviviq |
| Genentech USA, INC. | $13.10 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Keister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.